Table 4:
Haemodynamic thermodilution measurements recorded before surgery (baseline) and 1, 8 and 20 h after termination of extracorporeal circulationa
Adenosine group (n = 40) | Control group (n = 40) | P-valueb | ||
---|---|---|---|---|
CI (l min−1 m−2) | Baseline | 2.0 ± 0.4 | 2.3 ± 0.6 | 0.97 |
1 h | 2.1 ± 0.5 | 2.3 ± 0.6 | ||
8 h | 2.7 ± 0.6 | 3.0 ± 0.6 | ||
20 h | 2.8 ± 0.5 | 3.0 ± 0.5 | ||
LVSWI (g m m−2) | Baseline | 28.5 ± 8.6 | 30.7 ± 8.4 | 0.67 |
1 h | 22.8 ± 6.7 | 23.1 ± 7.3 | ||
8 h | 26.5 ± 5.8 | 31.1 ± 9.7 | ||
20 h | 28.3 ± 7.2 | 32.3 ± 9.2 | ||
MAP (mmHg) | Baseline | 75 ± 11 | 74 ± 12 | 0.28 |
1 h | 73 ± 11 | 74 ± 12 | ||
8 h | 72 ± 10 | 76 ± 11 | ||
20 h | 74 ± 12 | 76 ± 14 | ||
MPAP (mmHg) | Baseline | 21 ± 8 | 19 ± 6 | 0.59 |
1 h | 20 ± 5 | 19 ± 6 | ||
8 h | 21 ± 5 | 18 ± 4 | ||
20 h | 20 ± 5 | 19 ± 4 | ||
SVR (dyne s cm−5) | Baseline | 1644 ± 567 | 1384 ± 437 | 0.22 |
1 h | 1524 ± 477 | 1411 ± 643 | ||
8 h | 1126 ± 319 | 1068 ± 298 | ||
20 h | 1102 ± 289 | 1011 ± 225 | ||
PVR (dyne s cm−5) | Baseline | 187 ± 91 | 143 ± 74 | 0.68 |
1 h | 181 ± 90 | 134 ± 64 | ||
8 h | 173 ± 84 | 142 ± 55 | ||
20 h | 149 ± 65 | 119 ± 37 | ||
PCWP (mmHg) | Baseline | 13 ± 6 | 12 ± 5 | 0.68 |
1 h | 12 ± 5 | 12 ± 6 | ||
8 h | 11 ± 4 | 9 ± 4 | ||
20 h | 11 ± 4 | 11 ± 4 | ||
CVP (mmHg) | Baseline | 7 ± 4 | 6 ± 3 | 0.20 |
1 h | 8 ± 4 | 8 ± 4 | ||
8 h | 7 ± 3 | 7 ± 3 | ||
20 h | 8 ± 4 | 8 ± 4 | ||
HR (beats min−1) | Baseline | 61 ± 16 | 64 ± 15 | 0.36 |
1 h | 77 ± 12 | 84 ± 16 | ||
8 h | 84 ± 15 | 90 ± 14 | ||
20 h | 84 ± 13 | 85 ± 12 |
CI, cardiac index; CVP, central venous pressure; HR, heart rate; LVSWI, left ventricular stroke work index; MAP, mean arterial pressure; MPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.
aData are expressed as mean ± SD.
bSignificance test of effect of treatment allocation in repeated-measures ANOVA with baseline value subtracted from subsequent values.